The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
Open accessAbstract
Despite the success of immune checkpoint blockade against melanoma, many "cold" tumors like prostate cancer remain unresponsive. We found that hypoxic zones were prevalent across preclinical prostate cancer and resisted T cell infiltration even in the context of CTLA-4 and PD-1 blockade. We demonstrated that the hypoxia-activated prodrug TH-302 reduces or eliminates hypoxia in these tumors. Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperated to cure more than 80% of tumors in the transgenic adenocarcinoma of the mouse prostate-derived (TRAMP-derived) TRAMP-C2 model. Immunofluorescence imaging showed that TH-302 drives an influx of T cells into hypoxic zones, which were expanded by checkpoint blockade. Further, combination therapy reduced myeloid-derived suppressor cell density by more than 50%, and durably reduced the capacity of the tumor to replenish the granulocytic subset. Spontaneous prostate tumors in TRAMP transgenic mice, which completely resist checkpoint blockade, showed minimal adenocarcinoma tumor burden at 36 weeks of age and no evidence of neuroendocrine tumors with combination therapy. Survival of Pb-Cre4, Ptenpc-/-Smad4pc-/- mice with aggressive prostate adenocarcinoma was also significantly extended by this combination of hypoxia-prodrug and checkpoint blockade. Hypoxia disruption and T cell checkpoint blockade may sensitize some of the most therapeutically resistant cancers to immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In mouse models, hypoxic zones within tumors were shown to lack T cells (37, 38).”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [38]
In the citing paper
“High concentrations of oxygen activate the anticancer effects of T cells and NK cells by deactivating the adenosine immunosuppressive microenvironment. 127 , 206 , 408”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [127]
In the citing paper
“Considerable evidence in mouse models has shown that hypoxia promotes tumor escape from immune surveillance and immunotherapy13–19.”
In the citing paper
“there are also opposite reports showing that tumor hypoxia induces mouse T cell exhaustion and resistance to immunotherapy and depletion of HIF1α increases NK cell activity and tumor infiltration16,17,19,48,49.”
In the citing paper
“Current studies have focused on the role of hypoxia-induced metabolic reprogramming in causing T cell dysfunction and exhaustion16,19,52–55.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“In clinical trials, more than 50% of metastatic melanoma patients receiving this combination therapy achieved objective clinical responses, with the majority experiencing more than 85% reduction in tumor burden (2).”
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Self-citationL-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–410 of 410
Ren, X., Huang, F., & Yao, B. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100106
Mukherjee, A. G., Bharti, A. K., Mathew, D. M., Gopalakrishnan, A. V., & Nishu, S. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10274-9
Lazcano-Ornelas, A., & Tillu, N. (2026) · Lymphatics · doi:10.3390/lymphatics4030046
Potassium channels as an ionic checkpoint in tumor immunity
Wang, H., Zhang, Y., Jiang, S., Li, X., Zheng, Y., Wang, Y., Xu, Y., Xia, C., & Yan, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1907228
Spatial organization of intratumoral microbiome and regional tumor immunity
Bautista, J., & López‐Cortés, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1961794
Zhou, S., Bi, Y., Xiong, Z., Guo, Y., Cui, X., & Zhang, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105637
Deng, Z., Liu, H., Xi, S., Xie, M., He, Y., Jiang, T., Pingyu, F., Zhang, X., Liao, Z., Xiong, W., et al. (2026) · doi:10.65215/ltspreprints.2026.10.08.000360
Wu, H., Zhang, W., Yan, X., Ma, K., Colucci, M., Dong, Q. G., & Song, P. (2026) · Seminars in Immunopathology · doi:10.1007/s00281-026-01090-z
Fu, Z., Jackson-Patel, V., Farrand, K. J., Guise, C. P., Silva, S., Dabb, A., Lin, X., Liu, E., Ashoorzadeh, A., Smaill, J. B., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013057
Liu, D., Tang, J., Jiang, Y., Zhao, J., Shen, J., You, L., & Zheng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1979117
Metadata
- Authors
- Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., Shah, K., Balasubramanyam, S., Li, N., Wang, G., Ning, J., Zal, A., Zal, T., & Curran, M. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Curran, Michael A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-10-15
- Volume
- 128
- Issue
- 11
- Pages
- 5137-5149
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6205399
- OpenAlex
- W2890762462
- Cited by
- 399
- References
- 42
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 47 · 2023: 54 · 2022: 75 · 2021: 72 · 2020: 48 · 2019: 22 · 2018: 3
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Prevention Research Institute of Texas (RP170399)
- Cancer Research Institute (CLIP-Curran)
- National Cancer Institute (P50 CA140388)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- prostate cancer, tumor hypoxia, TH-302, hypoxia-activated prodrug, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint blockade, T cell infiltration, cold tumors, myeloid-derived suppressor cells, immunotherapy resistance, PTEN, SMAD4, neuroendocrine prostate cancer
- MeSH terms
- Adenocarcinoma, Animals, Immunotherapy, Male, Neoplasm Proteins, Neoplasms, Experimental, Nitroimidazoles, Phosphoramide Mustards, Prostatic Neoplasms, T-Lymphocytes, Cell Hypoxia, Mice, Knockout, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
